2023 Updates
- 1/26/2023 – Click here for important information
- 1/9/2023
In this quarterly update, Dr. Cassandra Calabrese provides an update on developments in COVID-19 since October 2022. Dr. Calabrese describes the current variants of concern that are rapidly increasing in prevalence. She discusses the therapies that are anticipated to have reduced efficacy against the latest omicron subvariants, highlighting subsequent changes to the recommendations for monoclonal antibody therapies for the prevention and treatment of COVID-19.
Click here for interview transcript
2022 Updates
- 10/3/2022
In this quarterly update, Dr. Cassandra Calabrese provides an update on developments in COVID-19 since July 2022. Dr. Calabrese lends her expertise in infectious disease and immunology as she describes the current variants of concern and available therapies. She also shares her thoughts on pressing patient and practitioner education needs regarding COVID-19 as we enter the fall respiratory virus season.
Click here for interview transcript - 7/11/2022
In this quarterly update, Dr. Cassandra Calabrese joins us to discuss key developments in COVID-19 since April 2022. Dr. Calabrese lends her expertise in infectious disease and immunology as she updates us on the current variants of concern – Omicron subvariants BA.4 and BA.5. She provides an overview of the currently available agents for pre-exposure prophylaxis and treatment of COVID-19 and discusses her thoughts regarding the upcoming fall respiratory virus season.
Click here for interview transcript - 4/4/2022
In this quarterly update, experts in infectious disease and immunology discuss key developments in COVID-19 since January 2022. In this interview, Drs. Leonard and Cassandra Calabrese highlight what we currently know regarding Omicron subvariant BA.2 and its response to available therapies. Faculty also provide updates on investigational therapies and summarize recent changes to the COVID-19 emergency use authorizations. - 1/3/2022
In this quarterly update, experts in infectious disease and immunology discuss key developments in COVID-19 management since October 2021. In this interview, Drs. Leonard and Cassandra Calabrese highlight the latest clinical data and summarize recent FDA approvals, emergency use authorizations, and guideline updates.
